A powerful tool for diagnosis and monitoring of medullary thyroid carcinoma (MTC)
- Thyroid carcinoma is the most common malignancy of the endocrine system - MTC is identified in up to 10% of all thyroid carcinoma patients
- These carcinoma produce elevated serum concentrations of calcitonin and so can be diagnosed with an exceptional degree of accuracy by immunoassays that measure serum calcitonin
- Calcitonin is a sensitive and specific tumor marker for the diagnosis and lifelong monitoring of MTC patients after thyroid surgery
||Serum, Li-heparin plasma, K2-EDTA plasma, K3-EDTA plasma
|Detection Limit*||LoB 0.3 pg/mL, LoD 0.5 pg/mL, LoQ 1 pg/mL with a total allowable error of ≤ 30 %|
||0.5 – 2,000 pg/mL
*LoB = Limit of Blank; LoD = Limit of Detection; LoQ = Limit of Quantitation (20 % total error).
Early, precise and reliable diagnosis of medullary thyroid carcinoma (MTC)
High specificity for MTC
- Calcitonin is a sensitive tool for diagnosis and follow up of MTC
- Calcitonin shows a high correlation with tumor burden, supporting early detection of new or residual disease
- Key guidelines recommend screening of calcitonin in all patients with thyroid nodules
High quality and accurate patient results
- High sensitivity and precision at low end concentrations ensure improved follow-up and monitoring
- Excellent precision across the entire measuring range supports accurate results
- High assay quality based on proven and leading Electrochemiluminescence (ECL) technology
The most complete automated thyroid portfolio – saving time and money
- Elecsys Calcitonin completes Roche’s leading automated thyroid marker portfolio to address a range of clinical needs in thyroid health management
- Having Elecsys Calcitonin and Elecsys Tg II on one platform allows the diagnosis of the majority of thyroid cancers
- All tests required for differential diagnosis of thyroid diseases are consolidated on one platform - including routine thyroid assays and special assays such as Elecsys Anti-Tg, Elecsys Anti-TPO and Elecsys Anti-TSHR
Calcitonin is a sensitive tool for diagnosis and follow up of MTC:
Costante, G. et al. (2009). Nat Clin Pract Endocrinol Metab 5, 35-44.
Cooper, D.S. et al. (2009). Thyroid 19(11), 1-48.
British Thyroid Association and Royal College of Physicians (2007). Guidelines for the management of thyroid cancer.
Pacini, F. et al. (2006). Eur J Endocrinol 154, 787–8037.
Kloos, R. et al. (2009). Thyroid 19, 565-612.
Key guidelines recommend screening of Calcitonin in all patients with thyroid nodules:
Elisei, R., Pinchera, A. (2012). Nature Reviews, Endocrinology 8, 467-475. British Thyroid Association and Royal College of Physicians (2007). Guidelines for the management of thyroid cancer.
Thyroid carcinoma is the most common malignancy of the endocrine system. In up to 10% of all thyroid carcinoma patients a medullary thyroid carcinoma (MTC) is identified:
U.S. National Library of Medicine, Medline Plus. Accessed 21 January 2013.
The diagnostic marker Calcitonin is a sensitive and specific tumor marker for the diagnosis as well as for the lifelong monitoring of MTC patients after thyroid surgery:
Elisei, R., Pinchera, A. (2012). Nature Reviews, Endocrinology 8, 467-475.